Evommune (EVMN) Income from Continuing Operations (2024 - 2026)

Evommune (EVMN) has 3 years of Income from Continuing Operations data on file, last reported at 113645000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 677.38% year-over-year to 113645000.0 in Q1 2026; TTM through Mar 2026 was 175518000.0, a N/A change from a year earlier, with the FY2025 full-year figure at 132251000.0, down 95.72% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 113645000.0, down from 27880000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for EVMN reached as high as 14619000.0 in Q1 2025 and fell as low as 113645000.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 35266333.33 across 3 years, with a median of 19769000.0 in 2024.
• Across the five-year window, Income from Continuing Operations retreated 21.73% in 2025 and slumped 677.38% in 2026, its largest moves.
• Year by year, Income from Continuing Operations stood at 20164000.0 in 2024, then tumbled by 38.27% to 27880000.0 in 2025, then tumbled by 307.62% to 113645000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 113645000.0 in Q1 2026, 27880000.0 in Q4 2025, and 19374000.0 in Q3 2025.